Harvard Health Blog
PCSK9 inhibitors: a major advance in cholesterol-lowering drug therapy
Posted March 15, 2015, 11:02 am, Updated March 20, 2015, 12:22 pm Gregory Curfman, M.D., Editor in Chief, Harvard Health Publications Every so often a medical advance comes along that rewrites the script for treating a disease or condition. After today’s announcements of impressive results of a new type of cholesterol-lowering drug, that scenario just might happen in the next few years.